SCHEMBL4587746

SCHEMBL4587746

CCN1CCN(Cc2cc(C(=O)Nc3ccc(C)c(Nc4nccn4-c4ncnc5[nH]ccc45)c3)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.56
MAPK14 Q16539 7/20 0.50
MAP3K7 O43318 7/20 0.50
MAP4K2 Q12851 7/20 0.50
LYN P07948 3/20 0.49
SRC P12931 3/20 0.49
INSR P06213 1/20 0.49
LCK P06239 1/20 0.49
HCK P08631 1/20 0.49
KDR P35968 1/20 0.49
DDR1 Q08345 1/20 0.47
CSK P41240 4/20 0.47
MAP3K20 Q9NYL2 4/20 0.47
EPHA2 P29317 3/20 0.47
MAP4K4 O95819 2/20 0.47
ABL1 P00519 2/20 0.47
RAF1 P04049 2/20 0.47
EPHB2 P29323 2/20 0.47
ABL2 P42684 2/20 0.47
EPHB4 P54760 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14097854 0.92 MAPK14 (0.47) CSF1RMAPK14MAP3K7MAP4K2LYN
SCHEMBL4587727 0.91 INSR (0.59) CSF1RMAPK14MAP3K7MAP4K2LYN
SCHEMBL4588859 0.86 MAPK14 (0.67) MAPK14MAP3K7MAP4K2LYNSRC
SCHEMBL13269773 0.86 LYN (0.62) CSF1RLYNSRCINSRLCK
SCHEMBL14097772 0.85 LYN (0.48) MAPK14MAP3K7MAP4K2LYNSRC
SCHEMBL3234488 0.84 CSF1R (0.60) CSF1RMAPK14MAP3K7MAP4K2LYN
SCHEMBL4586326 0.84 LYN (0.58) CSF1RMAPK14MAP3K7MAP4K2LYN
SCHEMBL4586222 0.84 PIKFYVE (0.57) CSF1RLYNSRCINSRLCK
SCHEMBL14097853 0.83 MAPK14 (0.54) MAPK14MAP3K7MAP4K2LYNSRC
SCHEMBL4588254 0.82 BRAF (0.59) CSF1RMAPK14MAP3K7MAP4K2LYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-08-07 US claimed
EP-1858521-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS IRM, LLC (BM) 2007-11-28 EP claimed
WO-2006101783-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-09-28 WO claimed
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-08-07 US disclosed
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors SRC, SGK2, PTK2B CSF1R 788/4885MAPK14 260/4885MAP3K7 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.